ReviewPublished 12 October 2026Antitumor immunity and immune-related toxicity during immune checkpoint inhibition: mechanistic overlap, tissue selectivity, and interventional evidenceChengyan Shi · Chunhai Li · Jun YanFrontiers in Immunologydoi 10.3389/fimmu.2026.1958441
ReviewPublished 12 October 2026Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integrationJingna WuFrontiers in Immunologydoi 10.3389/fimmu.2026.1911879
ReviewPublished 12 October 2026Progress in research on gut microbiota regulation of tumorigenesis, progression, and therapeutic response via inflammatory cytokinesYan Liu · Dan Zang · Jun ChenFrontiers in Immunologydoi 10.3389/fimmu.2026.1922678
Original ResearchPublished 12 October 2026SCD1 inhibition promotes lipid peroxidation and enhances anti-PD-1 response in triple-negative breast cancerQuentin Herrera Garfia · Aurélien Azam · Eric Bonneil · Laetitia Montero-Ruiz · Mohsen Momeni · Mohammad Farran · Robin Jehay · Nor Eddine SounniFrontiers in Immunologydoi 10.3389/fimmu.2026.1843935
Case ReportPublished 9 October 2026Durable partial response with low-dose, intermittent nivolumab in combination with gemcitabine for high PD-L1 metastatic triple-negative breast cancer: a case reportPo Lin Ooi · Jamin Munchar Elias · Francis Yew Fu TiengFrontiers in Oncologydoi 10.3389/fonc.2026.1964934
Original ResearchPublished 9 October 2026EQD2-adjusted mean lung dose and symptomatic pneumonitis after thoracic radiotherapy following immune checkpoint inhibitors in lung cancer: a single-center retrospective cohort studyXiqing Li · Libin Liu · Nuo Zheng · Nila Wang · Tingxiong Xiao · Xiaolong Lin · Haidun Chen · Qin Shi · Yuyin LeFrontiers in Oncologydoi 10.3389/fonc.2026.1923622
Original ResearchPublished 9 October 2026Adverse reactions of immune checkpoint inhibitors combined with acetaminophen/non-steroidal anti-inflammatory drugs (NSAIDs): a pharmacovigilance analysis of drug–drug interactionsXiayang Ren · Lihui Xue · Yanfeng Wang · Jian XiaoFrontiers in Pharmacologydoi 10.3389/fphar.2026.1833275
ReviewPublished 25 September 2026CLDN18 and FGFR2 splicing variants are emerging tumor-associated antigens for cancer therapyMasuko Katoh · Masaru KatohFrontiers in Molecular Medicinedoi 10.3389/fmmed.2026.1927389
ReviewPublished 23 September 2026Immunosuppressive cell populations as potential drivers of extrinsic immune checkpoint inhibition resistance in clear cell renal cell carcinomaUsman Humayun TemuriOncology Reviewsdoi 10.3389/or.2026.1953850
Case ReportPublished 4 September 2026Case Report: Pembrolizumab–induced myasthenia gravis with isolated anti-titin antibody positivity after thymectomy for thymomaJu Hye Kim · Ji Yeon Chung · Jeong Bin BongFrontiers in Drug Discoverydoi 10.3389/fddsv.2026.1932554
ReviewPublished 4 August 2026Beyond the hallmarks of cancer: enabling technologies reshaping cancer diagnosis, prevention, and treatmentSarfaraz K. NiaziOncology Reviewsdoi 10.3389/or.2026.1804447
Mini ReviewPublished 27 July 2026Glioblastoma as a neuro-immune network disorder: rethinking the tumor microenvironment, neural circuit integration, and therapeutic resistanceTyler Lo · Armando Bunjaj · Jeffrey P. Turnbull · Shivum Desai · Ammar Alsalahi · Heather Heitkotter · Daniel W. Griepp · Boyd F. RichardsOncology Reviewsdoi 10.3389/or.2026.1906725
Mini ReviewPublished 22 July 2026Leveraging ZBP1 signaling for cancer immunotherapyParth Desai · Chunxia Wen · Siddharth BalachandranFrontiers in Cell Deathdoi 10.3389/fceld.2026.1841599
ReviewPublished 7 July 2026Post-transplant lymphoproliferative disorder after solid organ transplantation: a comprehensive reviewLina Patricia Vargas-Nieto · Nicolás David Santoyo-Sarmiento · Maria Ballesteros-García · Angie Tatiana Calderón-Vásquez · Álvaro Daniel Pinto-Rodriguez · Maria Gabriela Robayo-Romero · Valeria Cormane-Alfaro · Jorge Daza-BuitragoFrontiers in Transplantationdoi 10.3389/frtra.2026.1869288
ReviewPublished 17 June 2026Fecal microbiota transplantation: from empirical remedy to precision medicineJunsheng Zhao · Yiming Fan · Keda Yang · Hainv GaoFrontiers in Microbiomesdoi 10.3389/frmbi.2026.1863308
Systematic ReviewPublished 5 June 2026Efficacy and safety of PD-1 inhibitors in recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysisAbdullah Alabbasi · Muhanad Alzahrani · Ziyad Alzahrani · Faris Sultan · Maha AlQahtani · Alaa SultanOncology Reviewsdoi 10.3389/or.2026.1745071
Letter to the EditorPublished 29 May 2026Remarkable effect of nivolumab on late liver metastasis recurrence in advanced malignant melanomaShoka Fukuizumi · Soichiro Kado · Takayo Ando · Atsuko Sato · Koji Kamiya · Takeo Maekawa · Mamitaro Ohtsuki · Mayumi KomineJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2026.16775
ReviewPublished 28 May 2026The interplay between bile acid metabolism and gut microbiome in biliary tract cancersIfeoma Ike · Farzad Teymouri · Christiana Crook · Sofia Guzman · Max Hazeltine · Dani Castillo · Daneng Li · Gagandeep BrarFrontiers in Microbiomesdoi 10.3389/frmbi.2026.1774429
Case ReportPublished 23 January 2026Case Report: Durable response to PD-1 blockade after failure of ALK-targeted therapy and chemoimmunotherapy in ALK-positive large B-cell lymphomaGuilherme Gasparini Spiandorelo · Ahmed Alnughmush · Olivia Crum · Dragan Jevremovic · J. C. VillasboasFrontiers in Hematologydoi 10.3389/frhem.2025.1683981
Science archivePublished 30 May 2025Fatal toxic epidermal necrolysis associated with an immune checkpoint inhibitorChiaki Seki · Yuta Koike · Misato Higuchi · Eri Ikenaga · Tomoka Waseda · Mio Ichiki · Daisuke Ehara · Motoi Takenaka · Keiko Kusano · Yuuki Sonoda · Hiroyuki MurotaJournal of Cutaneous Immunology and Allergydoi 10.3389/jcia.2025.14584
Molecular MedicinePublished 6 January 2025Immune-checkpoint-inhibitor therapy directed against PD-L1 is tolerated in the heart without manifestation of cardiac inflammation in a preclinical reversible melanoma mouse modelCaroline Schoenherr · Stefan Pietzsch · Cristina Barca · Franziska E. Müller · Frauke S. Bahr · Martina Kasten · Andre Zeug · Sergej Erschow · Christine S. Falk · Evgeni Ponimaskin · James T. Thackeray · Denise Hilfiker-Kleiner · Melanie Ricke-HochFrontiers in Molecular Medicinedoi 10.3389/fmmed.2024.1487526
Lab on a Chip TechnologiesPublished 10 September 2024The tumor microenvironment in therapy resistanceGuadalupe G. Garcia · Christopher J. Schmidt · Cynthia HajalFrontiers in Lab on a Chip Technologiesdoi 10.3389/frlct.2024.1420233
